Goldan Keith A.
Chief Financial Officer
Goldan Keith A. has filed 5 SEC Form 4 filings (8 transaction rows) across 2 companies, including SNDX, ABEO, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Jun 2, 2026.
On the most recent filing, Goldan Keith A. is listed as Chief Financial Officer at Syndax Pharmaceuticals Inc. Inside the rolling window, Goldan Keith A. reported no open-market purchases and 3 open-market sales totaling $137K in SNDX. The largest disclosed transaction in the window is a sale of 3,410 SNDX shares on Feb 9, 2026, worth $72K.
Companies traded
Other insiders at SNDX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$137K
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Goldan Keith A. made?
Goldan Keith A. has filed 5 SEC Form 4 filings (8 transaction rows) across 2 companies, including SNDX, ABEO since 2025.
Which companies does Goldan Keith A. trade?
Goldan Keith A. has filed SEC Form 4 disclosures for 2 companies, including SNDX, ABEO.
When was Goldan Keith A.'s most recent SEC Form 4 filing?
Goldan Keith A.'s most recent SEC Form 4 filing on Tracefour is dated Jun 2, 2026.
What is Goldan Keith A.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Goldan Keith A. is listed as Chief Financial Officer.
What is Goldan Keith A.'s total buy and sell value in the current window?
Inside the rolling retention window, Goldan Keith A. bought $0 and sold $137K based on SEC Form 4 filings.
What was Goldan Keith A.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 3,410 SNDX shares on 2026-02-09, worth $72K, per SEC Form 4 filings.